WeVote
Log In

Bill

Bill

HR 890

Stopping Pharma’s Ripoffs and Drug Savings For All Act

119th Congress Introduced by Pat Ryan

HR 890 aims to lower prescription drug costs by enforcing price transparency, capping increases, reducing out-of-pocket expenses, and holding pharma accountable for pricing.

Introduced in House
0
WeVote Research Nonpartisan
Bill Summary · HR 890

Summary of HR 890: Stopping Pharma’s Ripoffs and Drug Savings For All Act

Bill Number: HR 890
Introduced On: January 31, 2025
Current Status: Introduced in House
Referred To: House Committee on the Judiciary

Purpose and Intent

The Stopping Pharma’s Ripoffs and Drug Savings For All Act (HR 890) aims to address the rising costs of prescription medications in the United States. The bill seeks to implement measures that would enhance transparency in drug pricing, reduce out-of-pocket expenses for consumers, and hold pharmaceutical companies accountable for pricing practices that are deemed exploitative.

Key Provisions

HR 890 includes several significant provisions designed to achieve its goals:

  1. Price Transparency Requirements:

    • Pharmaceutical companies would be required to disclose the pricing structure of their drugs, including production costs, research and development expenses, and profit margins.
    • This information must be made available to both consumers and healthcare providers.

  2. Caps on Price Increases:

    • The bill proposes to limit annual price increases for prescription drugs to a certain percentage, potentially linked to inflation rates.
    • This provision aims to prevent sudden and excessive price hikes that can burden patients.

  3. Out-of-Pocket Cost Reductions:

    • HR 890 seeks to establish a framework for reducing out-of-pocket costs for patients, particularly for those with chronic conditions who rely on ongoing medication.
    • The bill may include provisions for co-pay assistance programs and subsidies for low-income individuals.

  4. Accountability Measures:

    • The legislation would introduce penalties for pharmaceutical companies that fail to comply with the new pricing transparency requirements.
    • It also aims to create a mechanism for consumers to report price gouging.

Who Would Be Affected

  • Consumers: Patients who rely on prescription medications would benefit from reduced costs and increased transparency regarding drug pricing.
  • Pharmaceutical Companies: The bill would impose new regulations and accountability measures on drug manufacturers, potentially affecting their pricing strategies and profit margins.
  • Healthcare Providers: Doctors and pharmacists would gain access to clearer pricing information, enabling them to make more informed decisions when prescribing medications.

Procedural Aspects

  • The bill was introduced and referred to the House Committee on the Judiciary on the same day, January 31, 2025.
  • Further legislative actions, including hearings and discussions within the committee, will determine the bill's progression through the House.

Conclusion

HR 890 represents a significant effort to reform the pharmaceutical industry by promoting fair pricing practices and enhancing consumer protections. If enacted, it could lead to substantial changes in how prescription drugs are priced and accessed in the United States, ultimately aiming to make medications more affordable for all Americans.

Compiled from official sources — confirm details with the bill’s official record.

Sign in to ask a question.